

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
20 January 2022 (20.01.2022)



(10) International Publication Number
WO 2022/013787 A1

(51) International Patent Classification:
A61P 27/02 (2006.01) *C07K 16/22* (2006.01)
(21) International Application Number:
PCT/IB2021/056363

(22) International Filing Date:
14 July 2021 (14.07.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/052,789 16 July 2020 (16.07.2020) US
63/156,709 04 March 2021 (04.03.2021) US

(71) Applicant: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35,
4056 Basel (CH).

(72) Inventors: **BIGELOW, Chad Eric**; Novartis Institutes
for BioMedical Research, Inc., 250 Massachusetts Ave-
nue, Cambridge, Massachusetts 02139 (US). **CARRION,
Ana Maria**; Novartis Institutes for BioMedical Research,
Inc., 250 Massachusetts Avenue, Cambridge, Massachu-
setts 02139 (US). **CHASTAIN, James Edgar**; Novar-
tis Institutes for BioMedical Research, Inc., 250 Massa-
chusetts Avenue, Cambridge, Massachusetts 02139 (US).
CLARK, Kirk Lee; Novartis Institutes for BioMedical Re-
search, Inc., 250 Massachusetts Avenue, Cambridge, Mass-
achusetts 02139 (US). **ETEMAD-GILBERTSON, Bijan
Alexandre**; 248 Moss Hill Road, Jamaica Plain, Massachu-
setts 02130 (US). **GHOSH, Joy Gispatti**; 566 Common-
wealth Avenue, Apartment 1001, Boston, Massachusetts
02215 (US). **HANKS, Shawn Michael**; Novartis Institutes
for BioMedical Research, Inc., 250 Massachusetts Avenue,
Cambridge, Massachusetts 02139 (US). **HAUBST, Nicole**;
Morphosys AG, Semmelweisstr. 7, 82152 Planegg (DE).
IYER, Ganesh Rajan; Novartis Institutes for BioMed-
ical Research, Inc., 250 Massachusetts Avenue, Cambridge,
Massachusetts 02139 (US). **MOKER, Nina**; Morphosys
AG, Semmelweisstr. 7, 82152 Planegg (DE). **NGUYEN,
Andrew Anh**; Novartis Institutes for BioMedical Research,
Inc., 250 Massachusetts Avenue, Cambridge, Massachu-
setts 02139 (US). **POOR, Stephen Hendrick**; Novartis In-
stitutes for BioMedical Research, Inc., 250 Massachusetts
Avenue, Cambridge, Massachusetts 02139 (US). **QIU, Yu-
bin**; Novartis Institutes for BioMedical Research, Inc., 250
Massachusetts Avenue, Cambridge, Massachusetts 02139
(US). **RANGASWAMY, Nalini Velamuri**; Novartis Insti-
tutes for BioMedical Research, Inc., 250 Massachusetts Ave-
nue, Cambridge, Massachusetts 02139 (US). **STEFANI-
DAKIS, Michael**; 15 Gibbs Street, Unit 3, Brookline,
Massachusetts 02139 (US). **TOKSOZ, Engin**; Morphosys

AG, Semmelweisstr. 7, 82152 Planegg (DE). **TWAROG,
Michael Zbigniew**; Novartis Institutes for BioMedical Re-
search, Inc., 250 Massachusetts Avenue, Cambridge, Mass-
achusetts 02139 (US).

(74) Agent: **NOVARTIS AG**; Lichtstrasse 35, 4056 Basel
(CH).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed
contained color or greyscale and is available for download
from PATENTSCOPE

(54) Title: ANTI-BETACELLULIN ANTIBODIES, FRAGMENTS THEREOF, AND MULTI-SPECIFIC BINDING MOLECULES

(57) Abstract: The present disclosure provides anti-BTC antibodies, methods of producing said antibodies, pharmaceutical composi-
tions comprising said antibodies, and methods of using said antibodies. The present disclosure also provides multi-specific binding
molecules, e.g., bispecific antibodies, comprising a BTC binding moiety and an anti-VEGF binding moiety.

WO 2022/013787 A1